Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.400-1.650 for the period, compared to the consensus earnings per share estimate of 1.278. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q3 2025 guidance to 0.300-0.370 EPS.
Omnicell Stock Down 4.0%
Omnicell stock traded down $1.25 during midday trading on Friday, hitting $29.76. 742,476 shares of the stock were exchanged, compared to its average volume of 500,803. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.74. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 59.52, a price-to-earnings-growth ratio of 9.05 and a beta of 0.76. The business's 50-day moving average price is $29.27 and its 200-day moving average price is $33.18. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.
Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. During the same period in the previous year, the company earned $0.51 earnings per share. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. On average, research analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on OMCL shares. Bank of America raised their price objective on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Wells Fargo & Company raised their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Benchmark decreased their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Piper Sandler restated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Omnicell presently has an average rating of "Moderate Buy" and a consensus target price of $45.33.
View Our Latest Stock Report on Omnicell
Institutional Investors Weigh In On Omnicell
Institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC grew its holdings in Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock valued at $348,000 after buying an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock valued at $4,337,000 after buying an additional 4,866 shares in the last quarter. AQR Capital Management LLC grew its holdings in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock valued at $627,000 after buying an additional 5,311 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock valued at $5,722,000 after buying an additional 109,382 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.
Omnicell Company Profile
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Stories
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
